ro 11-2933 has been researched along with Experimental Mammary Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alaoui-Jamali, MA; Batist, G; Centurioni, MG; Lehnert, S; Rustum, YM; Schecter, RL | 1 |
1 other study(ies) available for ro 11-2933 and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933.
Topics: Animals; Calcium Channel Blockers; Cell Division; DNA Damage; Doxorubicin; Drug Resistance; Female; Mammary Neoplasms, Experimental; Propylamines; Rats; Rats, Inbred F344; Tumor Cells, Cultured; Verapamil | 1993 |